Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab versus usual care in type 2 diabetes with mixed dyslipidemia
2015-001934-19Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alirocumab in combined dyslipidaemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percent change in non-high-density lipoprotein cholesterol. Started Jan 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
combined dyslipidaemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-001934-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001934-19.